NCT07163650

Evaluating Anti-Obesity Medications 6 Months After Metabolic Surgery

A Randomized, Double-Blind, Placebo-Controlled, Single-Center Study of Efsubaglutide Alfa in Patients Remaining Obese 6 Months After Metabolic Surgery

• Status: Recruiting
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Academic / Other
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Not accepted

Summary

This clinical trial aims to evaluate the weight-loss efficacy and safety of efsubaglutide alfa in patients who remain obese 6 months after metabolic surgery.

Detailed description

This study investigates the effects of efsubaglutide alfa intervention in patients with a body mass index (BMI) ≥28 kg/m² six months after metabolic surgery, aiming to determine whether it facilitates weight normalization and remission of obesity-related comorbidities, thereby assessing the weight-loss and metabolic benefits of early efsubaglutide alfa application in post-metabolic surgery obesity management.

Conditions

• Obesity
• Weight Loss
• Metabolic Surgery

Interventions

Type	Name	Description
DRUG	Efsubaglutide Alfa Injection	Efsubaglutide Alfa was injected daily in the morning before meals Subcutaneous injection at a dose of 1 mg/week in the first two weeks, increased to 3 mg/week in week 3, increased to 6 mg/week in week 5, up to 9 mg/2 week in week 13.
BEHAVIORAL	Diet and exercise guidelines	Participants followed a science-based diet and exercise program intervention.

Timeline

• Start date: 2025-09-16
• Primary completion: 2026-11-30
• Completion: 2027-02-28
• First posted: 2025-09-09
• Last updated: 2026-01-27

Locations

1 site across 1 country: China